Translational atherosclerosis research: From experimental models to coronary artery disease in humans

Abstract Atherosclerosis is the leading cause of death worldwide. Research on the pathophysiological mechanisms of atherogenesis has made tremendous progress over the past two decades. However, despite great advances there is still a lack of therapies that reduce adverse cardiovascular events to an...

Full description

Saved in:
Bibliographic Details
Published inAtherosclerosis Vol. 248; pp. 110 - 116
Main Author Gleissner, Christian A
Format Journal Article
LanguageEnglish
Published Ireland Elsevier B.V 01.05.2016
Subjects
Animals
Atherosclerosis
Atherosclerosis - physiopathology
Atherosclerosis - therapy
Cardiology - methods
Cardiovascular
Clinical trials
Clinical Trials as Topic
Coronary artery disease
Coronary Artery Disease - physiopathology
Coronary Artery Disease - therapy
Disease Models, Animal
Humans
Metabolic Syndrome - complications
Mice
Mice, Transgenic
Personalized medicine
Precision Medicine - methods
Therapy
Translational Medical Research - methods
Treatment Outcome
Clinical trials
Therapy
Research
Personalized medicine
Coronary artery disease
Atherosclerosis
Online AccessGet full text

Cover

More Information
Summary:Abstract Atherosclerosis is the leading cause of death worldwide. Research on the pathophysiological mechanisms of atherogenesis has made tremendous progress over the past two decades. However, despite great advances there is still a lack of therapies that reduce adverse cardiovascular events to an acceptable degree. This review addresses successes, but also questions, challenges, and chances regarding the translation of basic science results into clinical practice, i.e. the capability to apply the results of basic and/or clinical research in order to design therapies suitable to improve patient outcome. Specifically, it discusses problems in translating findings from the most broadly used murine models of atherosclerosis into clinically feasible therapies and strategies potentially improving the results of clinical trials. Most likely, the key to success will be a multimodal approach employing novel imaging methods as well as large scale screening tools–summarized as “omics” approach. Using individually tailored therapies, plaque stabilization and regression could prevent adverse cardiovascular events thereby improving outcome of a large number of patients.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0021-9150
1879-1484
DOI:10.1016/j.atherosclerosis.2016.03.013